BioWin and the Oncidium foundation Join Forces to Strengthen the Nuclear Medicine and Radiopharmaceutical Ecosystem in Belgium and Beyond
Brussels, BELGIUM – October 17, 2025 – The Oncidium foundation, an independent non-profit organization dedicated to ensuring equal access to radioligand therapy for cancer care, and BioWin, the Health-tech & biopharma Cluster of Wallonia, Belgium, today announced the signing of a Memorandum of Understanding (MoU) to collaborate in the field of nuclear medicine and radiopharmaceuticals.
The partnership aims to foster innovation, reinforce Belgium’s position as a European hub in nuclear medicine, and improve global patient access to advanced cancer care with Radioligand Therapy. Together, BioWin and the Oncidium foundation will support research, promote international visibility, and drive collaboration across the radiopharma ecosystem.
As part of this effort, the two organizations will align on strategic priorities related to expanding global access to life-saving radioisotopes, co-organize awareness and advocacy initiatives, and engage jointly with public authorities, hospitals, and research institutions. A joint steering committee, led by David Honba (BioWin) and Efrain Perini (Oncidium foundation), will oversee implementation and monitor progress.
“This collaboration with BioWin reinforces our belief that innovation in nuclear medicine must be driven by cooperation and shared purpose,” said Rebecca Lo Bue, CEO of the Oncidium foundation. “By combining BioWin’s strong regional network with our global mission, we can accelerate access to radioligand therapies and bring hope to more cancer patients.”
“We are thrilled to partner with the Oncidium foundation,” added Sylvie Ponchaut, General Director of BioWin. “Together, we will leverage Wallonia’s scientific excellence and Oncidium’s international reach to promote Belgium as a leading center for radiopharmaceutical innovation.”
This collaboration reflects both organizations’ commitment to ensuring that advances in nuclear medicine translate into tangible health benefits for patients worldwide.
